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Abstract
Background: Multiple sclerosis (MS) is an autoimmune inflammatory and neurodegenerative disease of the central
nervous system (CNS). It is widely accepted that inflammatory cells play major roles in the pathogenesis of MS,
possibly through the use of serine protease granzyme B (GrB) secreted from the granules of cytotoxic T cells. We
have previously identified GrB as a mediator of axonal injury and neuronal death. In this study, our goal was to
evaluate the effect of GrB inhibition in the human system in vitro, and in vivo in EAE using the newly isolated
GrB-inhibitor serpina3n.
Methods: We used a well-established in vitro model of neuroinflammation characterized by a co-culture system
between human fetal neurons and lymphocytes. In vivo, we induced EAE in 10- to 12-week-old female C57/BL6
mice and treated them intravenously with serpina3n.
Results: In the in vitro co-culture system, pre-treatment of lymphocytes with serpina3n prevented neuronal
killing and cleavage of the cytoskeletal protein alpha-tubulin, a known substrate for GrB. Moreover, in EAE, 50 μg
serpina3n substantially reduced the severity of the disease. This dose was administered intravenously twice at
days 7 and 20 post EAE induction. serpina3n treatment reduced axonal and neuronal injury compared to the
vehicle-treated control group and maintained the integrity of myelin. Interestingly, serpina3n treatment did not
seem to reduce the infiltration of immune cells (CD4+ and CD8+ T cells) into the CNS.
Conclusion: Our data suggest further studies on serpina3n as a potentially novel therapeutic strategy for the
treatment of inflammatory-mediated neurodegenerative diseases such as MS.
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Introduction
Multiple sclerosis (MS) is an inflammatory, neurodegener-
ative and demyelinating autoimmune disease of the cen-
tral nervous system (CNS) and is the most common cause
of non-traumatic chronic neurologic disability [1–3]. Neu-
rodegeneration is the main cause of disease progression in
MS patients [4]; however, the detailed mechanisms that
mediate this neuronal injury/death are not yet established
[5]. A known fact is that the level of lymphocyte infiltra-
tion into the CNS is well controlled under normal condi-
tions; in inflammatory disease states, however, unlimited
number of T-lymphocytes cross the blood brain barrier
(BBB) and enter the CNS compartment [6, 7]. These infil-
trating T-lymphocytes are abundantly found within MS
lesions [8, 9] and seem to be implicated in axonal path-
ology and neuronal death [10]. Indeed, we have previously
shown that anti-CD3 activated T cells induce severe
neurotoxic effect in both allogeneic and syngeneic systems
in vitro [11]. However, the mechanisms of T cell-mediated
neuronal injury/death have not been adequately explored.
Granzyme B (GrB) is a 32 kDa serine protease released
from the granules of cytotoxic T cells [12] or secreted by
T-lymphocytes when activated in vitro [13, 14]. There
are five types of granzymes in humans and about 11 in
mice [15, 16], but GrB is the most potent in both species
and well characterized [17]. It has been observed that
GrB expressing cytotoxic T cells are often found in close
proximity of oligodendrocytes or demyelinating axons in
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acute MS lesions [18] and are associated with neuronal
loss [19]. When these cytotoxic T cells come into con-
tact with a target cell, they deliver a “lethal hit” of cyto-
lytic molecules mainly constituted by perforin and GrB
[20–22]. These molecules induce target cell death by
disrupting a variety of intra/extracellular protein sub-
strates [23–25]. We have previously reported that active
MS lesions express high level of GrB. In vitro, granule-
purified human GrB induces severe neurotoxic effects
on human neurons to the same extent as activated T
cells do. This was further confirmed by the observation
that T cells isolated from GrB knockout BL6 mice were
not able to kill neurons derived from syngeneic naïve
mice [14]. In addition, T cell-mediated neurotoxicity was
reduced by decreasing the levels of GrB within T cells
[26]. We showed that purified human GrB internalizes
into neuronal cells possibly through M6P receptor and
induces neurotoxicity independent of perforin and in the
absence of lytic agent in the cytoplasm [14]. All of these
reports highlight GrB as a major player in T cell-mediated
neuronal injury/death in the context of inflammatory-
mediated neurodegenerative diseases such as MS and
makes GrB a potentially attractive therapeutic target for
these diseases.
In MS, the currently available disease-modifying treat-
ments such as interferon β and glatiramer acetate reduce
disease activity by ~30 % in relapsing and remitting MS
and ~45 % in clinically isolated syndromes. More effective
treatments such as immunosuppressants or monoclonal
antibodies have been associated with long term risks of
severe side effects in particular related to the interference
with whole subpopulations of lymphocytes and subse-
quent disruption of the mechanisms of immunosurveil-
lance [27–29]. Therefore, the development of new drugs
that have neuroprotective and enhanced repair mecha-
nisms without compromising some positive aspects of the
immune system such as immunosurveillance mechanisms
is currently needed [30]. We have previously identified a
novel GrB-inhibitor, serpina3n. It was isolated from mouse
Sertoli cells and forms a complex and stable covalent bond
with GrB and thereby inhibits the enzymatic activity of
the protease [31]. It has been shown that serpina3n re-
duces the rate of aortic rupture and death in a mouse
model of abdominal aortic aneurysm (AAA) by inhibiting
GrB-mediated decorin degradation and thereby enhancing
collagen remodeling [32]. Moreover, the same group
showed that topical administration of serpina3n accelerates
tissue repair and would healing in a mouse model of dia-
betics [33]. This strong inhibition of GrB activity makes
serpina3n a potentially novel therapeutic approach for
inflammation-mediated neurodegenerative diseases such as
MS. Therefore, in this study, we tested the hypothesis that
inhibition of GrB with serpina3n prevents inflammatory-
mediated neurodegeneration in vitro and in vivo in the
animal model of MS, experimental autoimmune encephalo-
myelitis (EAE).
Materials and methods
Culture of human fetal neurons and T cells
The University of Alberta Biomedical Ethics Committee
(UABEC) approved the collection of human brain tissue
from therapeutic abortions of 15-20 week fetuses, collec-
tion of blood samples from healthy volunteer donors
and isolation of human peripheral blood mononuclear
cells (PBMCs). The donor’s mother provided informed
consent in writing before donating the tissue. Blood do-
nors provided informed verbal consent, and their names
were registered in a blood donor registry before partici-
pating in the study. Human fetal neurons (HFNs) and
PBMCs (T cells) were isolated and cultured as previously
described [11]. All animal procedures and experiments
were approved by the University of Alberta Health
Sciences Laboratory Animal Services.
Killing assay and serpina3n inhibitory effect
T cells activation, using anti-CD3 and anti-CD28, and
killing assay pursued our previous protocol [14]. After 3
days, some portions of activated T cells (total PBMCs)
were incubated with a granzyme B-inhibitor serpina3n
(100 ng/ml) for 1 h prior to co-culturing with HFNs. To
assess the killing assay and inhibitory effect of serpina3n,
T cells were co-cultured with HFNs in a 1:1 ratio. The
control neuronal culture groups were treated with only
AIM-V medium or co-cultured with unactivated T cells.
The experimental groups were co-cultured with acti-
vated T cells, with Jurkat cells, supernatant pre-treated
activated T cells, or with serpina3n pre-treated activated
T cells, and the co-culture was kept for 24 h.
Immunocytochemistry and western blotting
Evaluation of immune-stained neurons was performed as
previously reported [14]. For serpina3n-inhibition study,
some groups of activated T cell cultures were incubated
with 100 ng/ml serpina3n for 2 h prior to co-culture.
Cleavage of the cytoskeletal protein was evaluated using
antibody against alpha-tubulin (α-tubulin) (1:3000) using
western blotting as previously described [14].
EAE induction and assessment
We induced EAE by subcutaneous immunization with
50 μg of myelin oligodendrocyte glycoprotein 35–55
(MOG35-55) in 10- to 12-week-old female C57BL/6 mice
(Charles River). The MOG35-55 was emulsified in complete
Freund’s adjuvant (CFA) (1 mg/ml to a final concentration
of 0.5 mg/ml CFA) (Sigma–Aldrich, Oakville, ON). An in-
traperitoneal injection of 300 ng/mouse Pertussis toxin
(Sigma–Aldrich, Oakville, ON) was administered at the
time of EAE induction and again 48 h later. Control mice
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were treated with CFA (0.5 mg/ml) and Pertussis toxin
alone and assessed following the procedures described in
previous reports [34, 35]. Briefly, after EAE induction, mice
were monitored daily, and the clinical signs of EAE were
graded on the following scale: Grade 0, normal mouse;
Grade 1, flaccid tail; Grade 2, mild hindlimb weakness with
quick righting reflex; Grade 3, severe hindlimb weakness
with slow righting reflex; Grade 4, hindlimb paralysis in
one hindlimb or both.
serpina3n treatments
Treatment of serpina3n followed different concentra-
tions at different time points. Cohorts of mice were
treated with 25 μg serpina3n either at day 7 post EAE
induction or at the disease onset of each animal. Other
groups of mice were treated with 50 μg serpina3n at
both days 7 and 20 post EAE induction. serpina3n was
injected via tail vein in a volume of 200 μl using 26G1/2
needle and 1 ml syringe (BD). The EAE experiment was
repeated for four times using N of 7–10 mice per each
group. A person blinded to the experimental groups per-
formed administration of serpina3n.
Immunohistochemistry and quantification of histology
After 36 days of evaluation, the mice were sacrificed and
tissues were processed as previously described [36].
Briefly, the following primary antibodies, rat anti-CD4, rat
anti-CD8 (both 1:200, Serotec), and a mouse anti-SMI32/
SMI312 (1:500, Wako), were used. The number of CD4+
T cells infiltrating the CNS parenchyma within the lumbar
portion of the spinal cord was counted in sections of both
control and serpina3n-treated groups. To assess axonal
damage, SMI32-positive axons were quantified in a similar
fashion. A cocktail of SMI32/312 antibody staining was
used to assess and quantify axonal/neuronal death.
An observer blind to the specific experimental condi-
tions of the tissue being analyzed carried out all image
analyses. In all the above assessments, three sections per
slide, two slides per animal, and n = 5 animals per group
were analyzed.
Myelin staining
To measure the status of demyelination of the tissues,
sections/slides were hydrated in descending alcohol con-
centrations. After washing in water for 1 min, slides were
stained in Eriochrome cyanin (EC) for 1 h. Following EC
staining, slides were differentiated in 0.5 % aqueous
NH4OH for 10 s and then coversliped using Permount
(Sigma).
Statistical analysis
Results were statistically analyzed using GraphPad Prism
5 and presented as mean ± SEM. The groups were com-
pared using ANOVA followed by the Tukey post hoc test
for normally distributed data. A two-tail unpaired t-test
was applied to compare two groups with normally distrib-
uted data. P values of <0.05 were considered significant.
Asterisks represent *P < 0.05 and **P < 0.01.
Results
serpina3n attenuates activated T cell-mediated neuronal
death
We have previously shown that activated T cells induce hu-
man neuronal death in vitro [11, 14] via the release of the
serine protease granzyme B [14]. Both CD4+ and CD8+ T
cells express GrB and induce neurotoxicity [13, 14]. We
also reported that GrB and serpina3n form a complex
interaction to the extent that the enzyme loses its activity
[31]. Hence, with the objective of preventing T cell-
mediated neuronal death, activated T cells (total PBMCs)
were pre-incubated with 100 ng/ml serpina3n for 1 h prior
to the co-culture with HFNs. Because serpina3n was
expressed in Jurkat cells [31], another control group of ac-
tivated T cells was pre-treated with supernatants collected
from non-serpin-expressing Jurkat cells. The positive
control was represented by neurons co-cultured with
activated T cells whereas the negative controls were neu-
rons co-cultured with either unactivated T cells or media
only. Quantification of MAP-2 immuno-reactive neurons
revealed that serpina3n treatment significantly reduced
activated T cell-mediated neuronal death whereas the
supernatant from control Jurkat cells not expressing serpi-
na3n did not show any neuroprotective effect. Average
neuronal survival in the groups co-cultured with activated
T cells or activated T cells pre-treated with Jurkat cell-
derived supernatant was about 30 %. On the contrary,
serpina3n treatment increased the neuronal survival to
about 60 % (Fig 1a; P < 0.05).
We have also previously shown that activated T cells or
GrB induce neuronal death by disrupting cytoskeletal pro-
teins such as alpha-tubulin, which is a primary substrate
for GrB in neurons [14]. Here, we assessed whether serpi-
na3n treatment prevents the cleavage of this cytoskeletal
protein. Western blotting showed that alpha-tubulin was
cleaved in the neurons co-cultured with activated T cells
or treated with GrB. On the contrary, the cleavage of
alpha-tubulin was absent in the neurons co-cultured with
serpina3n pre-treated activated T cells. Neurons in the
negative controls were treated with media only or co-
cultured with unactivated T cells, and no alpha-tubulin
cleavage was seen (Fig 1b).
serpina3n reduces the severity of the disease in EAE
Considering that serpina3n showed to be neuroprotec-
tive in vitro, we assessed the effect of serpina3n in vivo
in an animal model of MS, EAE. At day 7 post EAE
induction, mice were treated with a dose of 25 μg of ser-
pina3n and monitored until day 36. Day 7 was chosen
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considering that, after EAE induction, it takes about a
week for CNS inflammation. Another group of mice
received 25 μg serpina3n only when each mouse began
to show clinical signs of the disease. Treatment of the
mice with 25 μg serpina3n showed a slight trend toward
delaying the initiation as well as minimizing the severity
of the disease. However, the overall clinical score (mea-
sured as sum of scores-SOS) did not show any variation
between treated and untreated animals (data not shown).
Because of the slight trend we observed with the dose of
25 μg serpina3n, we decided to double the dose to 50 μg
of serpina3n. The injection of 50 μg serpina3n at day 7
post-induction delayed the onset of EAE and remarkably
reduced the severity of the disease until about day 20 of
the course of the experiment. However, this effect was not
sustained after day 20, and the clinical scores of untreated
and treated mice started to overlap so that the SOS was
not different (Fig 2a, b). Similarly, another group of mice
received 50 μg serpina3n at the onset of the symptoms.
Because of the variability of the onset of the disease, all
mice received the treatment at the same time when the
first mouse in that group began to show clinical signs of
EAE. Treatment with serpina3n at the onset of the disease
showed a similar trend to the treatment at day 7 post-
induction. serpina3n treatment reduced the severity of the
disease, but the effect of the drug was lost almost 14 days
post administration (Fig 2c, d). This indicated that serpi-
na3n was losing its effectiveness after 14 days of IV
administration and suggested that sequential dosing on
days 7 and 20 may be beneficial. This double administra-
tion was compared, in the same experiment, to a single
injection at day 7 post-induction. In this case, injection of
50 μg serpina3n at day 7 significantly delayed the onset
and severity of the disease. Because of the worsening of
clinical symptoms around day 20, a second injection with
an equal dose was performed at day 20. With this second
administration, the severity of the disease was significantly
decreased when compared to the control group. This was
shown by a significant difference in SOS between the
untreated and treated mice (Fig 3a, b; P < 0.05). Interest-
ingly, modal analysis revealed that almost all of the un-
treated mice were severely sick at Grade 4 whereas most
of the serpina3n-treated mice were below Grade 3 (Fig 3c;
P < 0.01).
serpina3n reduces axonal injury but does not block
infiltration of CD4+ and CD8+ T cells into the CNS
To assess whether the improvement of neurological dis-
ability in the serpina3n-treated mice was due to a reduc-
tion of axonal injury, immuno-staining was conducted
using non-phosphorylated anti-SMI32 antibody. Quanti-
fication of SMI32-positive axons in the contra-lateral
columns (see Additional file 1: Figure S1) in the lumbar
section of the spinal cord revealed that 50 μg serpina3n
significantly reduced (by about 50 %) the number of
injured axons in the treated mice compared to control
animals (Fig 4a, e, i; P < 0.05). The effect of serpina3n on
the transmigration and subsequent infiltration of inflam-
matory cells through the blood brain barrier is unknown.
Interestingly, quantification of CD4+ T cells in the lum-
bar section of the spinal cord revealed that the number
of infiltrating CD4+ T cells was equal in both control
and serpina3n-treated mice (Fig 4b, f, j). The infiltrating
T cells were in close apposition or proximity with the in-
jured axons (Fig 4d, h). The same was true for CD8+ T
cells; however, the number of infiltrating CD8+ T cells
was low in both groups (data not shown). We have pre-
viously shown that CD4+ and CD8+ T cells express GrB
and induce neuronal injury and death [13, 14]. CD4+ T
Fig. 1 serpina3n attenuates activated T cell-mediated neuronal killing
and alpha-tubulin cleavage. a Human fetal neurons were treated with
T cell media (control) or co-cultured with unactivated T cells, with
activated T cells, with Jurkat cells-derived supernatant-treated activated
T cells or with serpina3n-treated activated T cells. The culture was
immuno-stained using anti-MAP2 antibody. The control group was
taken as 100 %. serpina3n treatment significantly reduced T cell-
mediated neuronal killing (P < 0.05; data is pooled from at least three
different donors of neurons and T cells). b Western blotting showing
that the cytoskeletal protein, alpha-tubulin, remained intact in the
control group (neurons treated with media only), and in the groups in
which neurons were co-cultured with unactivated T cells. Alpha-
tubulin was cleaved in the neurons that were either treated with GrB
(positive control) or co-cultured with activated T cells. serpina3n
treatment prevented activated T cell-mediated cleavage of alpha-
tubulin (indicated by *)
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cell activation is also recently implicated in the progres-
sion of MS [37].
serpina3n reduces axonal injury
To assess the amount of axonal loss in the spinal cord, we
measured the areas within the white matter without
axons, also described as “black holes” as previously shown
[34]. We used a cocktail of antibodies that recognize both
the phosphorylated and non-phosphorylated forms of
neurofilaments to detect healthy and damaged axons in
the spinal cord. Sections were immuno-stained with a
cocktail of SMI32/312 antibodies. SMI32 stains a dephos-
phorylated form of 200-kdDa neurofilament subunit
(NF200) that appears in injured axons, whereas SMI312
recognizes the phosphorylated NF200 occurring in healthy
axons. Areas with no signals to the cocktail of antibodies
or lacking both the dephosphorylated and phosphorylated
NF200 subunit were used as markers of axonal loss.
Therefore, the percentage of the unstained lesion area or
black hole in relation to the total area of the column was
calculated in the dorsal and ventral columns of the spinal
cord. The lesion area (see arrow) was significantly larger
in the untreated control (Fig. 5a, c, for dorsal and ventral
columns, respectively) compared to the serpina3n-treated
mice (Fig. 5b, g). The actual values of the lesion areas are
9.9 % ± 1.7 in the control and 7.1 % ± 1.2 in the
serpina3n-treated mice (Fig. 5i; P < 0.05). Moreover, DAPI
counter-staining revealed that the lesion areas were filled
with abundant cells most likely infiltrating inflammatory
cells (Fig. 5b, d, f, h).
Myelin staining of the lower lumbar section of the
spinal cord with eriochrome cyanin revealed that the
integrity of myelin was severely compromised in the
control-untreated mice (Fig. 5j) when compared to the
serpina3n-treated group (Fig. 5k), indicating the poten-
tial role of serpina3n in preventing inflammation-
mediated demyelination.
Discussion
Extensive efforts are currently ongoing to develop new
therapeutic strategies for MS that interfere with the
underlying causes and mechanisms of neurodegeneration
[38]. In this study, we have assessed the neuroprotective
effect of GrB-inhibitor serpina3n both in vitro in the
human system and in vivo in an animal model of MS,
EAE. serpina3n is a member of the superfamily of serpins
(serine protease inhibitors), and we previously found that
it was the main protective factor in the Sertoli cell-
Fig. 2 serpina3n delays the onset and attenuates the severity of the disease in EAE. a Fifty μg of serpina3n was given at day 7 post EAE
induction, and a clinical evaluation followed for 36 days. Mice treated with serpina3n started to show EAE symptoms later than the control
group; the severity of the disease was lower in the treated group when compared to the untreated control group. b The graph shows SOS of “A”.
There is no significant difference between the treated and untreated group because the effect of serpina3n was lost after day 20 post EAE induction.
c Fifty μg of serpina3n was administered IV to the entire experimental group at once when the first mouse in the group showed EAE symptoms. The
effect of serpina3n was again lost after day 20/21. d There is no difference in SOS in “C” between the treated and untreated group
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conditioned media and a specific inhibitor of GrB [31].
Others also showed that gonadectomy significantly de-
creases the expression of serpina3n [39].
GrB is the main cytotoxic weapon released by T-
lymphocytes upon activation or encounter with foreign
antigens in the periphery. It is well documented that
inflammatory cells or cytotoxic T-lymphocytes induce
neuronal death [11, 14, 40]. Lymphocytes may possess
various lytic mechanisms to induce target cell apoptosis
[11, 41]; however, the major contributions seem to come
from GrB [17]. It has been previously shown that GrB
expressing T cells were in close proximity with demyeli-
nated axons in the parenchyma of acute MS lesions [18],
as well as with dying neurons in a rat model of spinal cord
injury and cerebral ischemia [42, 43]. In addition, GrB de-
ficient cytotoxic T cells fail to induce nuclear disruption in
target cells [24] highlighting the relevance of GrB in the
induction of neuronal injury in the mouse system [44].
In vitro, activated T cells released GrB into the media and
induced cytotoxicity in human neurons [45]. We have
shown that GrB enters neuronal cells through the
mannose-6-phosphate receptor and induces neuronal
apoptosis [14]. All of these reports confirm that GrB me-
diates neuronal injury and likely contributes to neurode-
generative processes. Inhibiting the enzymatic activity of
GrB could potentially be a novel therapeutic approach for
inflammatory-mediated neurodegenerative diseases of the
CNS such as multiple sclerosis.
Neurons are susceptible to activated T cell-induced
neurotoxicity in the absence of added antigen (Ag) and in-
dependent of MHC class I or II expression [11]. Most
infiltrating T-lymphocytes within MS lesions are Ag non-
specific, and T cells induce collateral bystander axonal
injury and neuronal death in the CNS [46–48]. We previ-
ously reported that activated T cells and/or GrB induce
neuronal death by disrupting the cytoskeletal protein
alpha-tubulin [14] indicating that alpha-tubulin is a pri-
mary substrate for GrB in neurons. This effect was
reversed by serpina3n treatment. Pre-treatment of acti-
vated T cells with serpina3n significantly reduced antigen-
independent T cell-mediated killing of human neurons in
vitro. In addition, western blotting showed that serpina3n
prevents activated T cell-mediated cleavage of alpha-
tubulin in neurons. Indeed, the interaction of serpina3n
with GrB leads to the loss of enzymatic activity of the
latter [31]. It has been previously shown that the release of
GrB within the target cell triggers cellular apoptosis by
cleaving a variety of protein substrates [23, 24, 49] includ-
ing cytoskeletal proteins [14]. Acute MS neuronal injury is
characterized by axonal transection and the formation of
Fig. 3 Two injections of 50 μg serpina3n significantly delay the onset and minimize the severity of the disease in EAE. a This representative graph
shows that 50 μg of serpina3n was administered IV at day 7 post EAE induction and delayed the onset of the disease in the treated group. A
second injection with the same dose of serpina3n was injected at day 20 and maintained the decreased severity of the disease. b Two injections
of 50 μg of serpina3n significantly reduced the SOS in the treated group compared to the untreated control (P < 0.05). c This graph shows the
modal distribution of the clinical scores. Most of the untreated control mice were severely sick at Grade 4, whereas most of the serpina3n-treated
mice were below Grade 3 (P < 0.01)
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axonal spheroids, suggestive of a cytoskeletal disruption
[50], and in EAE, T cells mediated the disruption of the
microtubule network within neurons [51].
Following our in vitro findings, we tested the hypothesis
that serpina3n would induce neuroprotection in EAE.
Treating EAE mice with a dose of 25 μg of serpina3n via
tail vein at day 7 post-induction slightly delayed the onset
of the disease. Treated mice showed decreased clinical
severity compared to vehicle-treated controls. However,
these differences were not significant most likely because
of the large amounts of GrB released by the inflammatory
cells and the inability to neutralize or antagonize its effects
by a single dose of serpina3n. For this reason, we tested a
double dose of serpina3n. Indeed, 50 μg serpina3n sub-
stantially delayed the onset of the disease and significantly
attenuated the severity of the disease when serpina3n was
given at both day 7 and 20 of post EAE induction. This
dose-response is in line with the recent finding that
serpina3n treatment reduces the rate of aortic rupture and
death in a mouse model of AAA in a dose-dependent
manner. In this model, serpina3n inhibits GrB-mediated
degradation of decorin, a proteoglycan that regulates col-
lagen spacing and fibrillogenesis [32]. In our experiments,
injection of 50 μg of serpina3n via the tail vein in a single
dose at day 7 post-induction led to a delay in the onset of
the disease symptoms, but by day 20 post-induction, the
clinical scores of the treated group were overlapping to
the control. To overcome this possible pharmacokinetic
effect, we decided to inject 50 μg serpina3n in two doses
at days 7 and 20 post-induction. In this case, we observed
not only a delay in disease onset but also a significant
attenuation of the clinical scores. This difference between
single dose and double dose could be related to pharma-
cokinetic of serpina3n and more studies are currently
ongoing in our laboratories to further define these
mechanisms.
Fig. 4 serpina3n significantly reduces axonal injury without interfering in the infiltration of CD4+ and CD8+ T cells to the CNS. Non-phosphorylated
SMI32 positive axons in tissue sections from a untreated control group, e serpina3n treated group. b Number of infiltrating CD4+ T cells into the
lumbar sections of untreated control mice and f Infiltrating CD4+ T cells in serpina3n-treated mice. c and g DAPI-stained cells in untreated control
and serpina3n-treated groups, respectively. d Merged micrograph from panels a, b, and c. h Merged micrograph from panels e, f, and g. (Scale bars,
50 μm). i Quantification of SMI32-positive axons in the control and serpina3n-treated groups (P < 0.05). j Quantification of infiltrating CD4+ T cells in the
control and serpina3n-treated groups
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Multiple sclerosis is characterized by inflammation,
demyelination, axonal/neuronal destruction, and scar/
plaque formation [52–54]. These features are commonly
represented in EAE [55]. In this study, serpina3n treat-
ment at the dose of 50 μg twice at days 7 and 20 post
EAE induction, significantly reduced axonal and neur-
onal injury, as well as area of the lesion when compared
to the vehicle-treated control mice. Areas completely
devoid of staining represent regions where significant
axonal loss has occurred. These “black holes” in the
tissue were filled with a significant number of DAPI-
positive nuclei most likely infiltrating inflammatory cells
[8, 9, 42, 43]. The infiltrating inflammatory cells were
observed in close contact/proximity with the injured
axons as shown in previous reports [18, 42, 43].
Delivering a specific T lymphocyte inhibitor is a major
interest in therapeutic strategies [56]. Interestingly in our
study, serpina3n treatment did not interfere with the infil-
tration of CD4+ and CD8+ T cells into the CNS. However,
the overall density of DAPI-stained cells seemed decreased
in the tissues from the serpina3n-treated mice compared
to the control. This suggests that serpina3n might have
additional inhibitory impact on the transmigration of
other cells such as macrophages and NK cells that could
use GrB for this process [57]. Similarly, others have re-
ported that there was no difference in the level of immune
cells infiltration between serpina3n-treated and sham-
treated groups in a mouse model of AAA [32]. This high-
lights that, in most cases, serpina3n is specifically targeting
GrB without interfering with the entry of some
Fig. 5 serpina3n significantly reduces inflammatory cell-mediated axonal death. In the untreated control group, representative micrographs
showing SMI32/312 immuno-reactive (a and c) and DAPI-stained (b and d) sections in the lumbar cord of the dorsal (a and b) and ventral
columns (c and d). In the serpina3n-treated group, representative micrographs showing SMI32/312 immuno-reactive (e and g) and DAPI-stained
(f and h) sections in the lumbar cord of the dorsal (e and f) and ventral columns (g and h). Arrows indicate the lesion area or “black hole”. (Scale
bars, 50 μm). i This graph shows that the percentage of lesion area/total area of the columns is significantly bigger in the untreated control group
when compared to serpina3n-treated group (P < 0.05). j and k serpina3n reduces the magnitude of demyelination. Eriochrome cyanin-stained
representative sections showing the scale of demyelination in untreated control (j) and serpina3n-treated (k) groups, respectively
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subpopulations of immune cells, particularly CD4+ and
CD8+ T-lymphocytes, into the CNS. This unique prop-
erty, which is absent in most of the disease-modifying
treatments currently available in the market to treat MS,
offers serpina3n a potential therapeutic advantage. Indeed,
completely blocking the entry of immune cells into the
CNS or affecting circulating immune cells and interfering
with the mechanisms of immunosurveillance might have
serious consequences as demonstrated by the cases of le-
thal infections that ensued treatments with drugs interfer-
ing with the amount of immune cells entering to the CNS
[27–29]. Although the effect of serpina3n on demyelin-
ation was not the primary objective of our study, we
observed decreased demyelination in the spinal cord of
EAE mice treated with serpina3n. This could suggest a
direct or indirect effect of GrB on myelin that would
require further investigations.
Altogether, it is widely accepted that inflammation plays
significant roles in the pathogenesis of neurodegeneration
in diseases such as MS. Among other mechanisms, in-
flammatory cells release serine proteases such as GrB and
induce axonal damage/neuronal death by disrupting vari-
ous extra-/intracellular proteins including cytoskeletal
proteins. The inhibition of the enzymatic activity of GrB
represents an appealing target for therapeutic intervention
of these conditions. serpina3n is a serine proteinase inhibi-
tor that forms a complex interaction with GrB and pre-
vents GrB-mediated axonal and neuronal injury, as well as
demyelination. In our experiments, serpina3n significantly
attenuated the severity of the disease in the animal model
of MS, EAE, without interfering with the infiltration of
CD4+ and CD8+ T cells into the CNS. Others also showed
that serpina3n was upregulated specifically in astrocytes in
ischemic stroke and LPS-induced neuroinflammation
models [58]. Our in vitro results robustly show that
serpina3n acts on GrB; however, it is also reported that
serpina3n reduces the expression levels of matrix metallo-
proteinases such as MMP-3 and MMP-9 in a mouse
model of cardiac remodeling [39]. These MMPs are impli-
cated in neuroinflammatory diseases such as MS and its
animal model EAE [59–61]. These findings suggest that
serpina3n may undergo complex mechanisms to attenuate
inflammation-mediated neurodegeneration. Further stud-
ies are warranted to explore serpina3n as well as human
analogs as potentially novel therapeutic strategies for
MS and other inflammatory-mediated neurodegenera-
tive diseases.
Additional file
Additional file 1: Figure S1. A representative section from the lumbar
part of the spinal cord. The regions under the blue-lined rectangular
boxes show the areas where CD4+ T cells and SMI32-positive axons were
quantified and analyzed. (PPTX 6495 kb)
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